Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Contineum Therapeutics stock last closed at $10.99, down 4.55% from the previous day, and has decreased 30.71% in one year. It has overperformed other stocks in the Biotechnology industry by 0.2 percentage points. Contineum Therapeutics stock is currently +228.06% from its 52-week low of $3.35, and -27.93% from its 52-week high of $15.25.
As of Dec 1, 2025, there are 29.18M shares of CTNM outstanding. The market capitalization of CTNM is $320.72M. In the past 24 hours, 135,000 CTNM shares were traded.
You need a brokerage account in order to access the NASDAQ market and buy CTNM shares.
Based on our experience, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, you need to fill out some personal details so you can invest in CTNM stock today.
Now that you've created your account on our top ranked stock trading app, you can securely and quickly fund your account:
Watch the walkthrough below to see the process of transferring funds into your investment account.
Once you have identified the best place to buy Contineum Therapeutics stock, it's very important to research their stock prior to investing, so you can wrap your head around the risk and upside.
WallStreetZen was designed to help everyday investors do better fundamental analysis.
You can see all of the due diligence checks on CTNM's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge CTNM's intrinsic value.
Using relative valuations methods:
You can access more valuation analysis on CTNM's stock here.
Out of 4 Wall Street analysts who give ratings on CTNM, the consensus analyst rating on Contineum Therapeutics is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are projecting on the Contineum Therapeutics stock forecast page.
Over the last 12 months, insiders at CTNM have not bought or sold any shares.
Research more about who owns CTNM stock here.
No, Contineum Therapeutics doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
There are two primary options:
Hit the Open Trade button and your broker will execute your order.
If you want more info about buying stocks on eToro, watch the how to video below:
Now that you own some CTNM shares, you'll want to keep up with your investment.
Add CTNM to a watchlist to track the most important metrics related to your CTNM stock.
To summarize, here are the 6 steps for buying Contineum Therapeutics stock:
If you require a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Contineum Therapeutics, create your watchlist below.